BioSyngen (Biotechnology) — Funding, Investors & Signals 2026

BioSyngen

A clinical stage biotech developing first-in-class cell therapies targeting solid and liquid tumors.

Founded 2016

Singapore 20 employees Series Unknown Total: $500.00M Biotechnology

BioSyngen is a Singapore-based biotechnology startup founded in 2016 with a clear focus on developing first-in-class cell therapies targeting solid and liquid tumors. The company has made significant strides in its clinical stage, with its first-in-class products entering Phase I/II clinical trials for nasopharyngeal cancer, lymphoproliferative disease, and lung cancer, with Orphan Drug Designation (ODD) and Fast-Track designation. The company strategically positions itself at the intersection of public-private biopharma ecosystem, driving its international strategy from its global headquarters in Singapore and its clinical center in Guangzhou, China. It also focuses on enriching its pipeline with further IND submissions and collaborates for breakthroughs, especially in translational R&D and clinical development. BioSyngen is committed to playing a pivotal role in accelerating drug development from bench-to-bedside. It has set up a Translational Medicine Centre, a public-private partnership that connects stakeholders in R&D, Clinical Development, Hospitals, Pharma, Enterprises, and Venture Capital. The company also has GMP cell therapy manufacturing facilities in two key locations - in Singapore and Guangzhou, thus covering global needs. Notably, BioSyngen secured its last investment of CNY500.00M in a Venture Round investment on 21 October 2021, with the SCI Group as the investor. As the company continues to progress in its mission to offer better prospects for cancer patients, it remains an intriguing proposition for investment and partnership opportunities in the biotech industry. For more information, visit their website at www.biosyngen.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	••••••	1		21 Oct 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

••••••

21 Oct 2021

FAQ About BioSyngen

A clinical stage biotech developing first-in-class cell therapies targeting solid and liquid tumors.

BioSyngen was founded in 2016.

BioSyngen is headquartered in Singapore.

BioSyngen operates in the following industries: Biotechnology.

BioSyngen has approximately 20 employees.

BioSyngen has completed 1 funding round, raising a total of $500.00M. The latest funding stage is Series Unknown.

Top alternatives and competitors to BioSyngen include SCG Cell Therapy, Lineage Cell Therapeutics, Elixiron Immunotherapeutics, CARsgen Therapeutics, Lyell Immunopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

BioSyngen and SCG Cell Therapy are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

BioSyngen

General Information

Track BioSyngen

Discover More

About BioSyngen

Funding Rounds & Investors (1)

BioSyngen Alternatives & Competitors

FAQ About BioSyngen

Don't just browse. Track.